Comparison of Selected Characteristics of SARS-CoV-2, SARS-CoV, and HCoV-NL63

Comparison of Selected Characteristics of SARS-CoV-2, SARS-CoV, and HCoV-NL63

The global pandemic known as coronavirus disease 2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review article presents the taxonomy of SARS-CoV-2 coronaviruses, which have been classified as the seventh known human pathogenic coronavirus. The etiolo...

Full description

Bibliographic Details
Main Authors:	Darina Bačenková, Marianna Trebuňová, Tatiana Špakovská, Marek Schnitzer, Lucia Bednarčíková, Jozef Živčák
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Series:	Applied Sciences
Subjects:	SARS-CoV-2 SARS-CoV HCoV-NL63 ACE2 receptor
Online Access:	https://www.mdpi.com/2076-3417/11/4/1497

Similar Items

A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs
by: David Pattinson, et al.
Published: (2022-03-01)

HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic
by: Elena Rita Simula, et al.
Published: (2020-12-01)

Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa
by: Lida C. Lesmes-Rodríguez, et al.
Published: (2023-02-01)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
by: Sébastien Pasquereau, et al.
Published: (2021-02-01)

Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV
by: Tiza L. Ng’uni, et al.
Published: (2024-01-01)

Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
by: Irene A. Abela, et al.
Published: (2024-02-01)

Seroconversion to HCoV-NL63 in Rhesus Macaques
by: Lia van der Hoek, et al.
Published: (2009-10-01)

A Comparison of Conserved Features in the Human Coronavirus Family Shows That Studies of Viruses Less Pathogenic than SARS-CoV-2, Such as HCoV-OC43, Are Good Model Systems for Elucidating Basic Mechanisms of Infection and Replication in Standard Laboratories
by: Audrey L. Heffner, et al.
Published: (2025-02-01)

Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1
by: Nehemya Friedman, et al.
Published: (2018-09-01)

Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients
by: Salum J. Lidenge, et al.
Published: (2024-03-01)

Robust Evaluation of Ultraviolet-C Sensitivity for SARS-CoV-2 and Surrogate Coronaviruses
by: S. J. Boegel, et al.
Published: (2021-10-01)

Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives
by: Cheng-Wei Yang, et al.
Published: (2020-12-01)

Nebulized CLODOS Technology Shows Clear Virucidal Properties against the Human Coronavirus HCoV-229E at Non-Cytotoxic Doses
by: Sabina Andreu, et al.
Published: (2021-03-01)

Prime editor‐mediated functional reshaping of ACE2 prevents the entry of multiple human coronaviruses, including SARS‐CoV‐2 variants
by: Wenwen Zhao, et al.
Published: (2023-10-01)

Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation
by: Jang Hoon Kim, et al.
Published: (2023-12-01)

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2
by: Haiyan Yan, et al.
Published: (2021-09-01)

Betacoronaviruses SARS-CoV-2 and HCoV-OC43 infections in IGROV-1 cell line require aryl hydrocarbon receptor
by: Meisam Yousefi, et al.
Published: (2023-12-01)

Comparative transcriptome analysis of SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoV-229E identifying potential IFN/ISGs targets for inhibiting virus replication
by: Yuzhuang Liu, et al.
Published: (2023-12-01)

Co-circulation of Four Human Coronaviruses (HCoVs) in Queensland Children with Acute Respiratory Tract Illnesses in 2004
by: Theo P. Sloots, et al.
Published: (2012-04-01)

Antibodies Against SARS-CoV-2 Do Not Cross-React with Endemic Coronaviruses in a Pediatric Population: Data from a Bangladesh Cohort
by: Ana Citlali Márquez, et al.
Published: (2025-01-01)

Comparative Study of SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-229E and Influenza Host Gene Expression in Asthma: Importance of Sex, Disease Severity, and Epithelial Heterogeneity
by: Mackenzie E. Coden, et al.
Published: (2021-06-01)

Influenza-like illness symptoms due to endemic human coronavirus reinfections are not influenced by the length of the interval separating reinfections
by: Ferdyansyah Sechan, et al.
Published: (2024-03-01)

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
by: Sean A. Lynch, et al.
Published: (2021-08-01)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
by: Virginia Fuochi, et al.
Published: (2023-03-01)

Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2
by: Sebastian Wirsching, et al.
Published: (2022-04-01)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)

The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients
by: Alessandro Marcello, et al.
Published: (2020-09-01)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
by: Jung Eun Huh, et al.
Published: (2021-04-01)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
by: Yun-yu Zhang, et al.
Published: (2020-08-01)

Structural Insights on the SARS-CoV-2 Variants of Concern Spike Glycoprotein: A Computational Study With Possible Clinical Implications
by: Marni E. Cueno, et al.
Published: (2021-10-01)

Development of Primer Panels for Whole-Genome Amplification and Sequencing of Human Seasonal Coronaviruses: hCoV-OC43, hCoV-HKU1, hCoV-229E, and hCoV-NL63
by: Tamila Musaeva, et al.
Published: (2024-12-01)

The therapeutic promises of Lianhuaqingke in the mice model of coronavirus pneumonia (HCoV-229E and SARS-CoV-2)
by: Mingye Wang, et al.
Published: (2021-10-01)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
by: Sophie Steiner, et al.
Published: (2020-12-01)

Editorial: Human coronavirus research: 20 years since the SARS-CoV outbreak
by: Burtram C. Fielding
Published: (2022-09-01)

Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4)
by: Ramanjit Kaur, et al.
Published: (2023-08-01)

A Serological Multiplexed Immunoassay (MIA) Detects Antibody Reactivity to SARS-CoV-2 and Other Viral Pathogens in Liberia and Is Configurable as a Multiplexed Inhibition Test (MINT)
by: Brien K. Haun, et al.
Published: (2024-03-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)

Long-Term Health Consequences of SARS-CoV-2: Assumptions Based on SARS-CoV-1 and MERS-CoV Infections
by: Ashutosh Khaswal, et al.
Published: (2022-07-01)

Autopsy Tool in Unknown Diseases: The Experience with Coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2)
by: Francesco Sessa, et al.
Published: (2021-03-01)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
by: Zeinab Abdelrahman, et al.
Published: (2020-09-01)